Knee fusion versus above knee amputation as two options to deal with knee periprosthetic joint infection

Background Periprosthetic joint infection (PJI) poses a significant challenge in total knee arthroplasty (TKA), with recurrence rates as high as 14–28%, leading to substantial morbidity and treatment costs. When conventional treatments fail, knee fusion and above-the-knee amputation (AKA) emerge as...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Archives of orthopaedic and trauma surgery 2024-12, Vol.144 (12), p.5229-5238
Hauptverfasser: Hoveidaei, Amir Human, Ghaseminejad-Raeini, Amirhossein, Esmaeili, Sina, Movahedinia, Mohammad, karbasi, Shima, Khonji, Mohammad Saeid, Nwankwo, Basilia Onyinyechukwu, Shrestha, Ashesh, Conway, Janet D.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Periprosthetic joint infection (PJI) poses a significant challenge in total knee arthroplasty (TKA), with recurrence rates as high as 14–28%, leading to substantial morbidity and treatment costs. When conventional treatments fail, knee fusion and above-the-knee amputation (AKA) emerge as alternative options. Existing literature offers conflicting views on the efficacy and impact of knee fusion versus AKA with varied outcomes and limitations. Methods This retrospective national study spanning 2010–2022 investigates Knee Fusion and AKA as options for addressing Knee PJI. Utilizing PearlDiver Patient Records Database, procedural, and reimbursement data on over 100 million individuals from all the US was evaluated. Readmission rates, costs, and complications of the mentioned procedures were assessed using ICD-9 and ICD-10 codes within a 90-day period and one-year post-operation. Statistical analyses, including chi-square tests and regression models, were conducted using integrated R software. Results The study reveals a substantial escalation ( p  
ISSN:1434-3916
0936-8051
1434-3916
DOI:10.1007/s00402-024-05429-9